Claris Bio

Claris Bio is a developer of topical formulation technologies for corneal wounds, ulcers, and scar treatments. The company's technology creates a recombinant hepatocyte growth factor that accelerates the healing process, enabling healthcare providers to access non-invasive treatments and allowing patients to recover faster and maintain health. Claris Bio's leading project brings a topical ocular bio-solution with dHGF to the eyes of patients with stage 2 and 3 neurotrophic keratitis (NK), a molecule with the potential to restore corneal structural and functional integrity.